- Home
- NB vs CDXS Comparison
NB vs CDXS Comparison
Compare NB & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NB
- CDXS
- Stock Information
- Founded
- NB 1987
- CDXS 2002
- Country
- NB United States
- CDXS United States
- Employees
- NB N/A
- CDXS N/A
- Industry
- NB Metal Mining
- CDXS Major Chemicals
- Sector
- NB Basic Materials
- CDXS Industrials
- Exchange
- NB Nasdaq
- CDXS Nasdaq
- Market Cap
- NB 150.3M
- CDXS 176.4M
- IPO Year
- NB N/A
- CDXS 2010
- Fundamental
- Price
- NB $2.43
- CDXS $2.46
- Analyst Decision
- NB Strong Buy
- CDXS Buy
- Analyst Count
- NB 2
- CDXS 2
- Target Price
- NB $4.13
- CDXS $11.00
- AVG Volume (30 Days)
- NB 2.4M
- CDXS 508.4K
- Earning Date
- NB 05-20-2025
- CDXS 05-14-2025
- Dividend Yield
- NB N/A
- CDXS N/A
- EPS Growth
- NB N/A
- CDXS N/A
- EPS
- NB N/A
- CDXS N/A
- Revenue
- NB N/A
- CDXS $59,345,000.00
- Revenue This Year
- NB N/A
- CDXS $12.62
- Revenue Next Year
- NB N/A
- CDXS $22.11
- P/E Ratio
- NB N/A
- CDXS N/A
- Revenue Growth
- NB N/A
- CDXS N/A
- 52 Week Low
- NB $1.27
- CDXS $1.90
- 52 Week High
- NB $4.15
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- NB 49.64
- CDXS 51.79
- Support Level
- NB $2.38
- CDXS $2.23
- Resistance Level
- NB $2.57
- CDXS $2.59
- Average True Range (ATR)
- NB 0.21
- CDXS 0.14
- MACD
- NB -0.05
- CDXS 0.05
- Stochastic Oscillator
- NB 24.66
- CDXS 70.45
About NB NioCorp Developments Ltd.
NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.